

CONTENTS

List of figures	i -vi
List of tables	vii–viii
List of abbreviations	ix - x
Preface	xi

S. No.	Title	Page No.
1.	1 Introduction	1-36
2.	1.1 Diabetes mellitus	1
3.	1.2 Types of DM	1
4.	1.2.1 Type 1 diabetes mellitus	1-2
5.	1.2.2 Type 2 diabetes mellitus	2-3
6.	1.2.3 Maturity onset diabetes of the young (MODY)	3
7.	1.2.4 Gestational diabetes	4
8.	1.3 Statistics of DM	4-7
9.	1.4 Symptoms of DM	7
10.	1.5 Mechanism	7
11.	1.5.1 Glucose metabolism (Inadequate and defective insulin secretion)	7-8
12.	1.5.2 Glucose transport and defect in transport activity	8-9
13.	1.5.3 Hormonal regulation for glucose metabolism	9
14.	1.6 Pathophysiology of DM	10
15.	1.6.1 Oxidative stress	10-11
16.	1.6.2 Insulin resistance	11-12
17.	1.6.3 Impaired insulin secretion	12-13
18.	1.6.4 Increased hepatic glucose and lipid production	13-14
19.	1.7 Tests for diabetes	15-16
20.	1.8 Treatment of DM	16
21.	1.8.1 Pharmacological agents	16
22.	1.8.1.1 Pharmacological treatment of type 1 diabetes	16-17
23.	1.8.1.2 Pharmacological treatment of type 2 diabetes	17-20
24.	1.8.2 Traditional and Ayurvedic medicine	20-24
25.	1.8.2.1 <i>Terminaliachebula</i> Retz.	24
26.	1.8.2.2 <i>Terminaliabelirica</i> Roxb.	26
27.	1.8.2.3 <i>Andrographispaniculata</i> Nees.	26
28.	1.8.2.4 <i>Berberisaristata</i> DC.	26
29.	1.8.2.5 <i>Nyctanthesarbor-tristis</i> L.	27
30.	1.8.2.6 <i>Premnaintegrifolia</i> L.	27
31.	1.9 Current drug (PHE) targets for DM	27-30
32.	1.9.1 Phytochemical content	30-32
33.	1.9.2 α -amylase and α - glucosidase enzymes	32-33
34.	1.9.3 Free radical scavenging activity	33-34
35.	1.9.4 Gut microbiotadysbiosis	34-35
36.	1.9.5 Short chain fatty acids content	35-36

37.	2 Literature review	37-48
38.	2.1 Medicinal plants and their antidiabetic activity	38-40
39.	2.1.1 <i>Andrographispaniculata</i>	40-41
40.	2.1.2 <i>Premnaintegrifolia</i>	41-42
41.	2.1.3 <i>Berberis</i>	42
42.	2.1.4 <i>Nyctanthes arbor-tristis</i>	42-43
43.	2.1.5 <i>Terminaliabellerica</i>	43
44.	2.1.6 <i>Terminaliachebula</i>	43-44
45.	2.1.7 <i>Cyperusrotundus</i>	44
46.	2.1.8 <i>Emblicaofficinalis</i>	44
47.	2.1.9 <i>Picrorhizakurroa</i>	44-45
48.	2.1.10 <i>Tinosporacordifolia</i>	45
49.	2.1.11 <i>Citrulluscolocynthis</i>	45
50.	3 Objective, rationale, and plan of work	49-52
51.	3.1 Objective	49
52.	3.2 Rationale	49-50
53.	3.3 Plan of work	50-52
54.	4 Materials and methods	53-84
55.	4.1 Chemicals and drugs	53
56.	4.2 Selection of plant materials	53-54
57.	4.3 Collection, authentication, and processing of plants source	54-55
58.	4.4 Method of preparation of extract	55
59.	4.5 Phytochemical investigation	56
60.	4.5.1 Preliminary phytochemical study	56
61.	4.5.2 Quantitative phytochemical study	56
62.	4.5.3 Total phenolic content determination	56
63.	4.5.4 Total flavonoid content determination	56-57
64.	4.6 Antioxidant capacity of each extract	57
65.	4.6.1 DPPH free radical scavenging assay	57
66.	4.7 Preparation of poly herbal extracts (PHE)	57
67.	4.8 Polyphenol content, flavonoid content and antioxidant capacity of PHE	58
68.	4.9 Selection of PHE	58
69.	4.9.1 ICP-MS determination of heavy metals	58
70.	4.9.2 <i>In vitro</i> anti-inflammatory activity of PHE	59
71.	4.9.2.1 Membrane stabilization assay	60
72.	4.9.2.2 Albumin denaturation inhibition	60
73.	4.9.3 <i>In vitro</i> anti-diabetic activity of PHE	61
74.	4.9.3.1 <i>In-vitro</i> α -amylase inhibition assay	61
75.	4.9.3.2 <i>In-vitro</i> α -glucosidase inhibition assay	61-62
76.	4.9.4 Anti-hyperglycemic activity through oral glucose tolerance test (OGTT)	62
77.	4.10 Chromatographic and spectroscopic analysis of PHE	62
78.	4.10.1 GC-MS analysis	62-63
79.	4.10.2 UPLC-Q-TOF-MS/MS analysis	63-64
80.	4.10.3 UHPLC-HRMS analysis	64

81.	4.10.4 Determination of quercetin, rutin and kaempferol by HPTLC	64-66
82.	4.11 Toxicity study of PHE	67
83.	4.11.1 Experimental animals and doses	67-68
84.	4.11.2 Acute oral toxicity assay	68
85.	4.11.3 Sub-acute toxicity assay	68-69
86.	4.11.4 Hematological study	69
87.	4.11.5 Liver function test	69
88.	4.11.6 Histopathology	70
89.	4.12 Anti-diabetic activity of PHE	71
90.	4.12.1 Experimental animals and doses	71-72
91.	4.12.2 Diabetes induction, animal group and treatment protocol	72
92.	4.12.3 Oral glucose tolerance test (OGTT) of PHE in DM rats	73
93.	4.12.4 Body weight, glucose level and biochemical indices estimation	73
94.	4.12.5 Insulin resistance and β -cell function scores	73-74
95.	4.12.6 Organ harvesting and analysis of samples	74
96.	4.12.7 RT-PCR analysis	74-75
97.	4.12.8 Histology and immunohistochemistry studies	75-76
98.	4.12.9 Quantification of the beta-cell area in the intact pancreas	76
99.	4.13 Gut microbiota dysbiosis study of PHE in diabetic rat model	76
100.	4.13.1 Fecal DNA extraction and sequencing	76-77
101.	4.13.2 Composition and diversity of the gut microbiota	77
102.	4.13.3 Determination of SCFAs by HPLC in the fecal sample	77-78
103.	4.14 Bioinformatics study of bioactive compounds in PHE	78
104.	4.14.1 Bioinformatic study for GC-MS identified bioactive compounds	78
105.	4.14.1.1 Compounds database construction and drug-likeness filtering	78
106.	4.14.1.2 Target genes related to selected compounds and DM	78-79
107.	4.14.1.3 Network construction of interconnection between active ingredients and overlapping genes	79
108.	4.14.1.4 Pathways and interactive analysis of hub genes	79
109.	4.14.1.5 Prediction of biological activity spectrum	80
110.	4.14.1.6 Binding affinity energy analysis of the uttermost ingredient on a hub gene by molecular docking test	80
111.	4.14.2 Bioinformatic study for HR-MS identified biomarker compounds	80
112.	4.14.2.1 Compounds database construction and drug-likeness filtering	80
113.	4.14.2.2 Collection of target genes related to biomarker compounds and DM	80-81
114.	4.14.2.3 Construction of protein-protein network	81
115.	4.14.2.4 Pathways and interactive analysis of hub genes	82
116.	4.14.2.5 Binding affinity energy analysis of the uttermost ingredient on a hub gene by molecular docking test	82
117.	4.14.3 Network pharmacology approach via compound-microbiota-signaling pathways-targets-metabolite network analysis	82
118.	4.14.3.1 Mining of metabolites from gut-microbiota	82
119.	4.14.3.2 Identification of the core gene of metabolite and DM	82-83
120.	4.14.3.3 PPI and compound target networks construction	83

121.	4.14.3.4 Estimation of the gene ontology (GO) and KEGG pathway	83
122.	4.14.3.5 Molecular docking of the gut microbiota metabolite with core gene	83
123.	4.15 Statistical Analysis	84
124.	5 Results	85-200
125.	5.1 Extraction yield of medicinal plants	85
126.	5.2 Phytochemical investigation of extracts	85
127.	5.2.1 Preliminary phytochemical study	85
128.	5.2.2 Determination of total phenolic content	85-86
129.	5.2.3 Determination of total flavonoid content	86
130.	5.2.4 Antioxidant capacity of extracts	88
131.	5.2.5 Comprehensive study of phenol, flavonoid contents and Antioxidant potential of PHE	88
132.	5.3 Heavy metals determination of PHE through ICP-MS	91
133.	5.4 <i>In vitro</i> anti-inflammatory activity of PHE	91
134.	5.4.1 Membrane stabilization assay	91-92
135.	5.4.2 Inhibition of albumin denaturation	92-93
136.	5.5 <i>In vitro</i> anti-diabetic activity of PHE	93
137.	5.5.1 α - Amylase inhibition assay	93
138.	5.5.2 α - Glucosidase inhibition assay	93-94
139.	5.6 Anti-hyperglycemic activity through oral glucose tolerance test (OGTT)	95
140.	5.7 Phytochemical investigation of PHE	96
141.	5.7.1 Bioactive contents from GC-MS	96
142.	5.7.2 Bioactive contents from UPLC-Q-TOF-MS/MS	97-98
143.	5.7.3 Bioactive components and UHPLC-HRMS metabolite profile of PHE	107-108
144.	5.7.4 Characterization and quantification of polyphenols	122
145.	5.7.4.1 Method validation	122
146.	5.8 Acute oral toxicity study	125
147.	5.9 Sub-acute oral toxicity study	127
148.	5.9.1 Hematological and serum biochemical analyses	128
149.	5.9.2 Histopathological analyses of vital organs	131-133
150.	5.10.1 OGTT in STZ induced DM	134
151.	5.10.2 Body weight of diabetic rats administered PHE	134
152.	5.10.3 Fasting blood glucose level	135
153.	5.10.4 Serum HbA1c, insulin, HOMA-IR, HOMA- β and biochemical levels of diabetic rats administered PHE	136
154.	5.10.5 Serum lipid parameters in experimental rats	137
155.	5.10.6 Antioxidant markers level	138
156.	5.10.7 Anti-inflammatory and antioxidant activities	139
157.	5.10.8 Changes in the histopathology of the pancreas	140
158.	5.10.8.1 Protection of beta cells against streptozotocin	141
159.	5.10.9 Effect of PHE on gut microbiota	148
160.	5.10.9.1 Alpha diversity	151
161.	5.10.9.2 Beta diversity	152
162.	5.10.9.3 Comparison of the gut microflora community composition	155-157

163.	5.10.9.4 Correlation of gut microflora with metabolic parameters	157
164.	5.10.9.5 SCFAs content of fecal sample	160
165.	5.10.9.6 Polyphenols in the enrichment of symbiotics	161-162
166.	5.10.9.7 Correlations between gut microbiota and lipid metabolism indexes	162
167.	5.11 Bioinformatics study of bioactive compounds identified in GC-MS	165
168.	5.11.1 ADMET and drug-likeness score	166
169.	5.11.2 Target genes associated with the compounds and DM	168
170.	5.11.3 Hub genes and essential active ingredients of PHE against DM	168-169
171.	5.11.4 Network construction, hub gene analysis and functional annotation of ATA against DM	170-171
172.	5.11.5 Potential molecular pathways of ATA against DM	171-172
173.	5.11.6 Activity spectra for substances (PASS)	176
174.	5.11.7 Molecular docking analysis	176
175.	5.11.7.1 Validation of top selected hub genes protein	176
176.	5.11.7.2 Affinity binding score of a key bioactive ingredient Alpha Tocospiro A on hub genes protein	176-177
177.	5.12 ADMET and drug-likeness score of biomarker compounds of PHE identified in LC-MS and HR-MS	181
178.	5.12.1 Network pharmacology analysis of the common targets and possible pathways regulated by biomarker compounds in DM	181-182
179.	5.12.2 Molecular docking assessment	187
180.	5.13 Acquisition of gut metabolites and their potential targets	190
181.	5.13.1 Identification of 8 core targets from metabolites and diabetes related targets	192
182.	5.13.2 Protein-protein interaction network analysis	193
183.	5.13.3 Identification of the 3 Kyoto encyclopedia of genes and genomes pathway enrichments and gene ontology enrichment analysis of the 3 components	196
184.	5.13.4 Molecular docking test	197
185.	6 Discussion	201-226
186.	7 Conclusion	227-228
187.	8 future scope	229-230
188.	Bibliography	231-256
189.	Publications	257-262
190.	Appendix	
191.	Curriculum vitae	
